Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;26(7):759-65.
doi: 10.1089/aid.2009.0276.

Incident neuropathy in HIV-infected patients on HAART

Beau K Nakamoto  1 , Aaron McMurtray, James Davis, Victor Valcour, Michael R Watters, Bruce Shiramizu, Dominic C Chow, Kalpana Kallianpur, Cecilia M Shikuma
Affiliations

Incident neuropathy in HIV-infected patients on HAART

Beau K Nakamoto et al. AIDS Res Hum Retroviruses. 2010 Jul.

Abstract

We determined the incidence of and risk factors for distal sensory polyneuropathy (DSP) in individuals on HAART. Sixty-one HIV-positive subjects on HAART for at least 6 months and neuropathy free were retrospectively selected. The study included subjects who had previously tolerated d-drugs without developing DSP. Neuropathy incidence over 4 years was calculated. Cox proportional hazards models were used to determine risk factors associated with incident DSP. Nineteen subjects developed DSP over a mean follow-up of 2.4 years. Subjects never treated with a d-drug developed DSP at a rate of 21 cases per 100 person-years (95% CI, 8.9-33.7). Subjects with a history of d-drug treatment but not on a d-drug at enrollment developed DSP at a rate of 17 cases per 100 person-years (95% CI, 2.1-31.8). Those on d-drug treatment developed DSP at a rate of 25 cases per 100 person-years (95% CI, 8.7-41.6). Multivariable analysis identified age [hazard ratio (HR) = 1.09; p < 0.01] and low CD4(+) nadir [hazard ratio (HR) = 0.79; p = 0.03] as significant risk factors. Current or prior history of treatment with d-drug was not a significant risk factor for incident DSP in subjects who had previously tolerated d-drug treatment without developing a toxic DSP. Age and low CD4(+) are risk factors for incident DSP. However, current or prior history of d-drug treatment is not a significant risk factor for incident DSP in subjects who had previously tolerated d-drug treatment without developing a toxic DSP.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Flow chart of subject selection and outcome.
See this image and copyright information in PMC

References

    1. Sacktor N. Lyles RH. Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–260. - PubMed
    1. Morgello S. Estanislao L. Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. Arch Neurol. 2004;61(4):546–551. - PubMed
    1. Skopelitis EE. Kokotis PI. Kontos AN, et al. Distal sensory polyneuropathy in HIV-positive patients in the HAART era: An entity underestimated by clinical examination. Int J STD AIDS. 2006;17(7):467–472. - PubMed
    1. Smyth K. Affandi JS. McArthur JC, et al. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006. HIV Med. 2007;8(6):367–373. - PubMed
    1. So YT. Holtzman DM. Abrams DI. Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol. 1988;45(9):945–948. - PubMed

Publication types

Substances